A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma

References

• Hoyos V, Borrello I. The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies. Blood. 2016 Sep 29;128(13):1679–1687.
   PubMed Web of Science ®Google Scholar
• Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017 Aug 24;17(9):543–556.
   PubMed Web of Science ®Google Scholar
• Lomas OC, Tahri S, Ghobrial IM. The microenvironment in myeloma. Curr Opin Oncol. 2020 Mar;32(2):170–175.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Smyth MJ, Martinet L. Cancer immunoediting and immune dysregulation in multiple myeloma. Blood. 2020;136(24):2731-2740.
   Google Scholar
• Chen D, Tang P, Liu L, et al. Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway. Cell Cycle. 2018;17(7):858–867.
   PubMed Web of Science ®Google Scholar
• Franssen LE, Mutis T, Lokhorst HM, et al. Immunotherapy in myeloma: how far have we come? Ther Adv Hematol. 2019;10:2040620718822660.
   Web of Science ®Google Scholar
• Paiva B, Azpilikueta A, Puig N, et al. PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma. Leukemia. 2015 Oct;29(10):2110–2113.
   PubMed Web of Science ®Google Scholar
• Tamura H, Ishibashi M, Sunakawa-Kii M, et al. PD-L1-PD-1 pathway in the pathophysiology of multiple myeloma. Cancers (Basel). 2020 Apr 10;12(4):924.
   Web of Science ®Google Scholar
• Greil C, Engelhardt M, Ihorst G, et al. Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. Haematologica. 2019 Feb;104(2):370–379.
   PubMed Web of Science ®Google Scholar
• Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001 Jul 1;98(1):210–216.
   PubMed Web of Science ®Google Scholar
• Pierceall WE, Amatangelo MD, Bahlis NJ, et al. Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-treated patients with relapsed/refractory multiple myeloma. Clin Cancer Res. 2020 Nov 15;26(22):5895–5902.
   PubMed Web of Science ®Google Scholar
• Kwon M, Kim CG, Lee H, et al. PD-1 blockade reinvigorates bone marrow CD8(+) T cells from patients with multiple myeloma in the presence of TGFbeta inhibitors. Clin Cancer Res. 2020 Apr 1;26(7):1644–1655.
   PubMed Web of Science ®Google Scholar
• Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019 Sep;33(9):2266–2275.
   PubMed Web of Science ®Google Scholar
• Costa L, Parameswaran H, Kumar S, et al. Overall survival of triple class refractory, penta-exposed multiple myeloma (mm) patients treated with selinexor plus dexamethasone or conventional care: a combined analysis of the storm and mammoth studies. Blood. 2019;134(Suppl_1):Abstract3125.
   Google Scholar
• Giuliani N, Accardi F, Marchica V, et al. Novel targets for the treatment of relapsing multiple myeloma. Expert Rev Hematol. 2019 Jul;12(7):481–496.
   PubMed Web of Science ®Google Scholar
• Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018 Mar;19(3):370–381.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, Bortezomib, and Dexamethasone for multiple myeloma. N Engl J Med. 2016 Aug 25;375(8):754–766.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, Lenalidomide, and Dexamethasone for multiple myeloma. N Engl J Med. 2016 Oct 6;375(14):1319–1331.
   PubMed Web of Science ®Google Scholar
• Kaufman J, Usmani S, San-Miguel J, et al. Four-year follow-up of the phase 3 Pollux study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) alone in Relapsed or Refractory Multiple Myeloma (RRMM). Blood. 2019;134(Suppl_1):Abstract1866.
   Google Scholar
• Dimopoulos M, Terpos E, Boccadoro M, et al. Apollo: phase 3 randomized study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2020;136(Suppl_1):Abstract412.
   Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015 Aug 13;373(7):621–631.
   PubMed Web of Science ®Google Scholar
• Van De Donk N, Usmani SZ. CD38 antibodies in multiple myeloma: mechanisms of action and modes of resistance. Front Immunol. 2018;9:2134.
   PubMed Web of Science ®Google Scholar
• Van De Donk NW, Moreau P, Plesner T, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood. 2016 Feb 11;127(6):681–695.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Nahi H, Plesner T, et al. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol. 2020 Jun;7(6):e447–e455.
   PubMed Web of Science ®Google Scholar
• Spencer A, Lentzsch S, Weisel K, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018 Dec;103(12):2079–2087.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, San-Miguel J, Belch A, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018 Dec;103(12):2088–2096.
   PubMed Web of Science ®Google Scholar
• Seckinger A, Hillengass J, Emde M, et al. CD38 as immunotherapeutic target in light chain Amyloidosis and Multiple Myeloma-association with molecular entities, risk, survival, and mechanisms of upfront resistance. Front Immunol. 2018;9:1676.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Nahi H, Legiec W, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020 May;7(5):e370–e380.
   PubMed Web of Science ®Google Scholar
• Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017 Aug 24;130(8):974–981.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020 Jul 18;396(10245):186–197.
   PubMed Web of Science ®Google Scholar
• Facon T, Kumar S, Plesner T, et al. Daratumumab plus Lenalidomide and Dexamethasone for untreated myeloma. N Engl J Med. 2019 May 30;380(22):2104–2115.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020 Jan 11;395(10218):132–141.
   PubMed Web of Science ®Google Scholar
• Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019 Jul 6;394(10192):29–38.
   PubMed Web of Science ®Google Scholar
• Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020 Aug 20;136(8):936–945.
   PubMed Web of Science ®Google Scholar
• Deckert J, Wetzel MC, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res. 2014 Sep 1;20(17):4574–4583.
   PubMed Web of Science ®Google Scholar
• Jiang H, Acharya C, An G, et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016 Feb;30(2):399–408.
   PubMed Web of Science ®Google Scholar
• Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 Dec 7;394(10214):2096–2107.
   PubMed Web of Science ®Google Scholar
• Moreau P, Dimopoulos MA, Yong K, et al. Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design. Future Oncol. 2020 Jan;16(2):4347–4358.
   PubMed Web of Science ®Google Scholar
• Raab MS, Engelhardt M, Blank A, et al. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1–2a trial. Lancet Haematol. 2020 May;7(5):e381–e394.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Patel K, Hari P, et al. A phase Ib study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed/refractory multiple myeloma (RRMM): preliminary results. J clin oncol. 2020;38(5_suppl):Abstract8539.
   Google Scholar
• Franssen LE, Stege CAM, Zweegman S, et al. Resistance mechanisms towards CD38-directed antibody therapy in multiple myeloma. J Clin Med. 2020 22; 9(4): Apr.
   Web of Science ®Google Scholar
• Alici E, Chrobok M, Lund J, et al. Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach. Br J Haematol. 2016 Aug;174(3):473–477.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Lonial S, Betts KA, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018 Oct 15;124(20):4032–4043.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med. 2018 Nov 8;379(19):1811–1822.
   PubMed Web of Science ®Google Scholar
• Usmani S, Ailawadhi S, Sexton R, et al. Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamthasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211). J clin oncol. 2020;38(15_suppl):Abstract8507.
   Web of Science ®Google Scholar
• Vij R, Nath R, Afar DEH, et al. First-in-human phase I study of ABBV-838, an antibody-drug conjugate targeting SLAMF7/CS1 in patients with relapsed and refractory multiple myeloma. Clin Cancer Res. 2020 May 15;26(10):2308–2317.
   PubMed Web of Science ®Google Scholar
• Tai YT, Acharya C, An G, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016 Jun 23;127(25):3225–3236.
   PubMed Web of Science ®Google Scholar
• Cho SF, Anderson KC, Tai YT. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: potential uses of BCMA-based immunotherapy. Front Immunol. 2018;9:1821.
   PubMed Web of Science ®Google Scholar
• Ghermezi M, Li M, Vardanyan S, et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017 Apr;102(4):785–795.
   PubMed Web of Science ®Google Scholar
• Sanchez E, Li M, Kitto A, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012 Sep;158(6):727–738.
   PubMed Web of Science ®Google Scholar
• Lonial S, Lee HC, Badros A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020 Feb;21(2):207–221.
   PubMed Web of Science ®Google Scholar
• Trudel S, Lendvai N, Popat R, et al. Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018 Dec;19(12):1641–1653.
   PubMed Web of Science ®Google Scholar
• Lonial S, Lee H, Badros A, et al. DREAMM-2: single-agent Belantamab Mafodotin (Belamaf) in patients with Relapsed/Refractory Multiple Myeloma (RRMM) – 1-year outcomes by prior therapies. Blood. 2020;136(Suppl_1):Abstract1417.
   Google Scholar
• Popat R, Nooka A, Stockerl-Goldstein K, et al. DREAMM-6: safety, tolerability and clinical activity of Belantamab Mafodotin (Belamaf) in combination with Bortezomib/Dexamethasone (BorDex) in Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2020;136(Suppl_1):Abstract1419.
   Google Scholar
• Trudel S, McCurdy A, Sutherland H, et al. Part 1 results of a dose finding study of Belantamab Mafodotin (GSK2857916) in combination with Pomalidomide (POM) and Dexamethasone (DEX) for the treatment of Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2020;136(Suppl_1):Abstract725.
   Google Scholar
• Kumar S, Migkou M, Bhutani M, et al. Phase 1, first-in-human study of MEDI2228, a BCMA-targeted ADC in patients with Relapsed/Refractory Multiple Myeloma. Blood. 2020;136(Suppl_1):Abstract179.
   Google Scholar
• Rasche L, Weinhold N, Morgan GJ, et al. Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev. 2017 Apr;55:190–199.
   PubMed Web of Science ®Google Scholar
• Bruins W, Zheng W, Higgins J, et al. TAK-169, a novel recombinant immunotoxin specific for CD38, induces powerful preclinical activity against patient-derived Multiple Myeloma Cells. Blood. 2020;136(Suppl_1):Abstract1363.
   Google Scholar
• Topp MS, Duell J, Zugmaier G, et al. Anti-B-cell maturation antigen BiTE Molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol. 2020 Mar 10;38(8):775–783.
   PubMed Web of Science ®Google Scholar
• Harrison S, Minnema M, Lee H, et al. A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM). Blood. 2020;136(Suppl_1):Abstract181.
   Google Scholar
• Garfall A, Usmani S, Mateos M, et al. Updated phase 1 results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood. 2020;134(Suppl_1):Abstract180.
   Google Scholar
• Cohen A, Harrison S, Krishnan A, et al. Initial clinical activity and safety of BFCR4350A, a FcRH5/CD3 T-cell-engaging bispecific antibody, in Relapsed/Refractory Multiple Myeloma. Blood. 2020;134(Suppl_1):Abstract292.
   Google Scholar
• Chari A, Berdeja J, Oriol A, et al. A phase 1, first-in-human study of Talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) x CD3 Bispecific Antibody, in patients with Relapsed and/or Refractory Multiple Myeloma (RRMM). Blood. 2020;134(Suppl_1):Abstract290.
   Google Scholar
• Costa L, Wong S, Bermúdez A, et al. First clinical study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): interim Results of a Phase 1 Multicenter Trial. Blood. 2019;134(Suppl_1):Abstract143.
   Google Scholar
• Madduri D, Rosko A, Brayer J, et al. REGN5458, a BCMA x CD3 Bispecific Monoclonal antibody, induces deep and durable responses in patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2020;134(Suppl_1):Abstract291.
   Google Scholar
• Lesokhin A, Levy M, Dalovisio A, et al. Preliminary safety, efficacy, pharmacokinetics, and pharmacodynamics of Subcutaneously (SC) administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 bispecific antibody, in patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2020;134(Suppl_1):Abstract3206.
   Google Scholar
• Rodriguez C, D’Souza A, Shah A, et al. Initial results of a Phase I study of TNB-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in Relapsed/Refractory Multiple Myeloma. Blood. 2020;134(Suppl_1):Abstract293.
   Google Scholar
• Nadeem O, Anderson KC. The safety of current and emerging therapies for multiple myeloma. Expert Opin Drug Saf. 2020 Mar;19(3):269–279.
   PubMed Web of Science ®Google Scholar
• Wu L, Seung E, Rao E, et al. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation. Nature Cancer. 2020;1(1):86–98.
   PubMedGoogle Scholar
• Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017 Sep 7;130(10):1189–1197.
   PubMed Web of Science ®Google Scholar
• Mateos MV, Blacklock H, Schjesvold F, et al. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019 Sep;6(9):e459–e469.
   PubMed Web of Science ®Google Scholar
• Ribrag V, Avigan DE, Green DJ, et al. Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013. Br J Haematol. 2019 Aug;186(3):e41–e44.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Schjesvold F, Oriol A, et al. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematol. 2019 Sep;6(9):e448–e458.
   PubMed Web of Science ®Google Scholar
• Sun J, Muz B, Alhallak K, et al. Targeting CD47 as a novel immunotherapy for multiple myeloma. Cancers (Basel). 2020 Jan 28;12(2):2.
   Web of Science ®Google Scholar
• Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis Relapsed Multiple Myeloma. J Clin Oncol. 2018 Aug 1;36(22):2267–2280.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Garfall AL, Stadtmauer EA, et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest. 2019 Mar 21;129(6):2210–2221.
   PubMed Web of Science ®Google Scholar
• Costello C, Cohen A, Patel K, et al. Phase 1/2 study of the safety and response of P-BCMA-101 CAR-T cells in patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with novel therapeutic strategies. Blood. 2020;136(Suppl_1):Abstract134.
   Google Scholar
• Madduri D, Berdeja J, Usmani S, et al., Phase 1b/2 study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma. Blood. 136(Suppl_1): Abstract177. 2020.
   Google Scholar
• Mailankody S, Jakubowiak A, Htut M, et al. Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011). J clin oncol. 2020;38(15_suppl):Abstract8504.
   Web of Science ®Google Scholar
• Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019 May 2;380(18):1726–1737.
   PubMed Web of Science ®Google Scholar
• Munshi NC, Anderson LD Jr., Shah N, et al. Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021 Feb 25;384(8):705–716.
   PubMed Web of Science ®Google Scholar
• Kumar S, Baz R, Orlowski R, et al. Results from Lummicar-2: a phase 1b/2 study of fully human B-cell maturation antigen-specific CAR T Cells (CT053) in patients with Relapsed and/or Refractory Multiple Myeloma. Blood. 2020;134(Suppl_1):Abstract133.
   Google Scholar
• Alsina M, Shah N, Raje N, et al. Updated results from the phase I CRB-402 study of anti-Bcma CAR-T cell therapy bb21217 in patients with Relapsed and Refractory Multiple Myeloma: correlation of expansion and duration of response with T cell phenotypes. Blood. 2020;134(Suppl_1):Abstract130.
   Google Scholar
• Jain T, Knezevic A, Pennisi M, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Adv. 2020 Aug 11;4(15):3776–3787.
   PubMed Web of Science ®Google Scholar
• Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019 Apr;25(4):625–638.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Lobato LG, Ganzetti M, Fernandez De Larrea C, et al. CAR T-cells in Multiple Myeloma: state of the art and future directions. Front Oncol. 2020;10:1243.
   PubMed Web of Science ®Google Scholar
• Li C, Mei H, Hu Y, et al. A bispecific CAR-T cell therapy targeting Bcma and CD38 for Relapsed/Refractory Multiple Myeloma: updated results from a phase 1 dose-climbing trial. Blood. 2019;134(Suppl_1):Abstract930.
   Google Scholar
• De Larrea CF, Staehr M, Lopez AV, et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven Relapse in Multiple Myeloma. Blood Cancer Discov. 2020 Sep;1(2):146–154.
   PubMedGoogle Scholar
• Pont MJ, Hill T, Cole GO, et al. gamma-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019 Nov 7;134(19):1585–1597.
   PubMed Web of Science ®Google Scholar
• Zah E, Nam E, Bhuvan V, et al. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat Commun. 2020 May 8;11(1):2283.
   PubMed Web of Science ®Google Scholar
• Al-Homsi S, Anguille S, Brayer J, et al. Clinical development of a non-gene-edited Allogeneic Bcma-Targeting CAR T-cell product in Relapsed or Refractory Multiple Myeloma. Blood. 2020;136(Suppl_1):Abstract1428.
   Google Scholar
• Mailankody S, Matous J, Liedtke M, et al. Universal: an allogeneic first-in-human study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma. Blood. 2020;136(Suppl_1):Abstract129.
   Google Scholar
• Van Der Schans JJ, Van De Donk N, Mutis T. Dual targeting to overcome current challenges in Multiple Myeloma CAR T-Cell treatment. Front Oncol. 2020;10:1362.
   PubMed Web of Science ®Google Scholar
• Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020 Feb 6;382(6):545–553.
   PubMed Web of Science ®Google Scholar
• Da-Via M, Dietrich O, Truger M, et al. Biallelic deletion of chromosome 16p encompassing the bcma locus as a tumor-intrinsic resistance mechanism to bcma-directed car t in multiple myeloma. HemaSphere. 2020;4(S1): AbstractEP883. EHA Abstract Book.
   PubMedGoogle Scholar
• Samur MK, Fulciniti M, Aktas Samur A, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021 Feb 8;12(1):868.
   PubMed Web of Science ®Google Scholar
• Da Via MC, Dietrich O, Truger M, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. 2021 Feb;22. 10.1038/s41591-021-01245-5
   PubMed Web of Science ®Google Scholar
• Bjorklund CC, Kang J, Amatangelo M, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020 Apr;34(4):1197–1201.
   PubMed Web of Science ®Google Scholar
• Wong L, Lamba M. Dolores Jiménez Nuñez M, et al. Dose- and schedule-dependent immunomodulatory effects of the novel CELMoD Agent CC-92480 in patients with Relapsed/Refractory Multiple Myeloma. Blood. 2020;136(Suppl_1):Abstract2295.
   Google Scholar
• Lonial S, Van De Donk N, Popat R, et al. First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). J clin oncol. 2019;37(15_suppl):Abstract8006.
   Web of Science ®Google Scholar
• Richardson P, Vangsted A, Ramasamy K, et al. First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). J clin oncol. 2020;38(15_suppl):Abstract8500.
   Google Scholar
• Van De Donk N, Popat R, Larsen J, et al. First results of Iberdomide (IBER; CC-220) in combination with Dexamethasone (DEX) and Daratumumab (DARA) or Bortezomib (BORT) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2020;136(Suppl_1):Abstract724.
   Google Scholar
• Heaney JLJ, Campbell JP, Iqbal G, et al. Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia. 2018 Aug;32(8):1727–1738.
   PubMed Web of Science ®Google Scholar
• Kourelis TV, Villasboas JC, Jessen E, et al. Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies. Blood Cancer J. 2019 Aug 28;9(9):72.
   PubMedGoogle Scholar
• Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood. 2019 Feb 14;133(7):660–675.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016 Jun 16;127(24):2955–2962.
   PubMed Web of Science ®Google Scholar